


# HARMONY



# ALLIANCE

## **Introducing HARMONY PLUS: a new public-private partnership within the HARMONY Alliance is being launched on October 1st, 2020.**

**HARMONY and HARMONY PLUS, two ongoing public-private partnerships within the HARMONY Alliance, are utilizing the HARMONY Big Data Platform to improve outcomes for patients with blood cancers**

**HARMONY PLUS will build up on the success of [HARMONY](#), which is currently using the power of Big Data to speed up the development of improved treatments and more effective strategies for patients with blood cancer. In addition to expanding the focus to other hematologic malignancies that were not initially covered in HARMONY, HARMONY PLUS Integrated Services will boost the power of Big Data by collaborating with other international big data initiatives and expanding access. New Artificial Intelligence (AI) techniques will be applied to enhance analytical capabilities and increase the accuracy of the results. By adapting the platform and tools to be used by hospitals and clinicians to improve patient outcomes, HARMONY PLUS aims to bring the results to where the patient is.**

HARMONY has made rapid progress since its launch in January 2017. By the end of 2019, HARMONY had identified 45,000 data sets from patients with various types of blood cancer and is targeting a data pool of 100,000 patients during the lifetime of the project. Furthermore, the [HARMONY Big Data Platform](#) represents a unique resource, meeting the highest standards of security and data governance.

This success calls for an expansion to include other important blood cancers currently not covered in HARMONY. Moreover, the value of the HARMONY Big Data Platform can be enhanced by greater collaborations with similar initiatives outside the EU, and by enabling the use of the latest learnings and developments in the field of big data analytics and artificial intelligence (AI) for healthcare. This will be achieved by the HARMONY PLUS.

HARMONY PLUS was established with funding from the [Innovative Medicine Initiative \(IMI\)](#) and involves 39 partners and 8 Associated Partners from 10 countries.

**[#bigdataforbloodcancer: Enabling Better and Faster Treatment for Patients with Hematologic Malignancies.](#)**



## How does HARMONY PLUS relate to HARMONY?

Like HARMONY, HARMONY PLUS uses Big Data to improve the management of blood cancers. Both projects are public-private partnerships (PPP) supported by IMI. Both HARMONY and HARMONY PLUS will cover all hematological malignancies.

HARMONY PLUS will leverage the lessons learned, the scientific knowledge and the technological platform already developed in HARMONY to unlock a greater potential of Big Data the application of Artificial Intelligence (AI) to healthcare challenges. As there is no need to reinvent the wheel, the project will hit the ground running.

HARMONY and HARMONY PLUS will share a common presentation to the world and a shared web site.

## HARMONY PLUS Objectives:

- Expand the scope of the Alliance to cover the remaining haematological malignancies not included in the HARMONY project.
- Scope the possibility to set up a HaemoDataBank repository for more information on patient samples throughout Europe.
- Design Integrated Services.

## HARMONY PLUS Partners:

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON; FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA; CHARITE - UNIVERSITAETSMEDIZIN BERLIN; GMV SOLUCIONES GLOBALES INTERNET; ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA; LEUKANET; EUROPEAN HEMATOLOGY ASSOCIATION (EHA); SYNAPSE RESEARCH MANAGEMENT PARTNERS; UNIVERSITAET ULM; ELN FOUNDATION; ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM; UNIVERSIDAD DE NAVARRA; UNIVERSITA DEGLI STUDI DI TORINO; VUMC; THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE; FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS; EUROPEAN RESEARCH INITIATIVE ON CLL; MASARYKOVA UNIVERZITA; THE LYMPHOMA STUDY ASSOCIATION; LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN; GROUPE FRANCOPHONE DES MYELODYSPLASIES; FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS; UNIVERSITY OF NEWCASTLE UPON TYNE; GPOH GEMEINNUTZIGE GMBH; OSPEDALE PEDIATRICO BAMBINO GESU; EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION; HELSINGIN YLIOPISTO; GENOME RESEARCH LIMITED; MEDISAPIENS; MLL MUNCHNER LEUKAMIELABOR; NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE; AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS; BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE; NOVARTIS PHARMA; CELGENE; BAYER; MENARINI; PFIZER.

**HARMONY Partners, [click here >](#) |**

**HARMONY Patient Cluster, [click here >](#)**

**HARMONY Associated Members, [click here >](#)**

[www.harmony-alliance.eu](http://www.harmony-alliance.eu) | [@harmonyNetEU](https://twitter.com/harmonyNetEU)

## Backgrounder

### **Which blood cancers are targeted by HARMONY and which by HARMONY PLUS?**

HARMONY focusses on Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma (NHL) and Pediatric Hematologic Malignancies.

HARMONY PLUS is widening the scope of HARMONY to cover myeloproliferative (MPN) disorders and other hematological malignancies. The new targets are Chronic Myeloid Leukemia (CML), Polycythaemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis; Hodgkin's Lymphoma, Waldenström Macroglobulinaemia and other rare blood cancers.

### **How are patients involved?**

Patients are a fundamental source of real-world data, but their contribution and specific expertise has long been a secondary priority in discussions about real-world evidence (RWE). HARMONY PLUS will provide an increased focus on RWE and the involvement of patient advocacy organisations.

The HARMONY Patient Cluster, a unique group of seven pan-European patient umbrella organizations which are active in HARMONY's hematological malignancies, was an integral part of the HARMONY Alliance right from the start. The patient community has actively contributed e.g. to the review of Big Data research proposals, the definition of Core Outcome Sets, and the project's ethics and data anonymisation procedures.

Within its broadened disease scope, HARMONY PLUS will expand its Stakeholders and Patients' Organisations Forum to enable additional pan-European patient organizations as well as nurses organisations to contribute and co-create in the different workstreams of HARMONY PLUS.

## Backgrounder | continued

### **What are the HARMONY PLUS Integrated Services?**

The Big Data Platform established by HARMONY is a unique and mature tool to advance the understanding of many hematological malignancies. Analyses are addressing many unmet needs, including the definition of better treatment strategies for individual patients, prediction of adverse events in specific subpopulations and definition of standard sets of relevant outcome measures.

HARMONY PLUS Integrated Services will take the Big Data Platform to the next level by expanding access to existing and emerging analytics tools.

A number of collaborations with international population databases are underway. As most blood cancers are very rare, the value of this expanded database will be much greater than the sum of its parts.

HARMONY PLUS will also advise on the analytics tools suitable for specific projects (scientific, regulatory or other).

### **How will the value of the HARMONY Big Data Platform be boosted by HARMONY PLUS?**

The HARMONY Big Data Platform represents a powerful resource for multidisciplinary researchers, clinical professionals and data scientists.

Through the HARMONY PLUS Integrated Service, the scope of the HARMONY Big Data Platform will be expanded, which will increase the power of analysis.

HARMONY and HARMONY PLUS will work hard and in a coordinated manner to provide data analysis tools in formats that can be adopted by hospitals and used by clinicians to improve HM patient's outcomes.

[#bigdataforbloodcancer: Enabling Better and Faster Treatment for Patients with Hematologic Malignancies.](#)

[www.harmony-alliance.eu](http://www.harmony-alliance.eu) | [@harmonyNetEU](#)

## Corporate Profile



### Public-private partnerships for Big Data in Hematology.



**HARMONY:** Established in January 2017. Unlock and spread valuable knowledge on 7 hematologic malignancies (blood cancers) among a large number of stakeholders. HARMONY aims to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies. HARMONY currently has 53 Partners and 41 Associated Members from 17 countries.



**HARMONY PLUS:** Established in October 2020. Unlock and spread valuable knowledge on 3 more hematologic malignancies (blood cancers). HARMONY PLUS will enable the use of the latest learnings and developments in the field of big data analytics and artificial intelligence (AI) for healthcare. HARMONY PLUS involves 39 partners and 8 Associated Partners from 10 countries.

**HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.**

The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026 and grant agreement No. 945406. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

[#bigdataforbloodcancer: Enabling Better and Faster Treatment for Patients with Hematologic Malignancies.](#)

[www.harmony-alliance.eu](http://www.harmony-alliance.eu) | [@harmonyNetEU](https://twitter.com/harmonyNetEU)